Revision 1

Store at -20C

#39091

MCP-1 Antibody (Carboxy-terminal Antigen)

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355) orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W, IP	H	Endogenous	13-15	Rabbit	#P13500	6347

Product Usage Information

Application	Dilution
Western Blotting	1:1000
Immunoprecipitation	1:50

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity/Sensitivity

MCP-1 Antibody (Carboxy-terminal Antigen) recognizes endogenous levels of total MCP-1 protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human MCP-1 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

Monocyte chemoattractant protein-1 (MCP-1), also known as CCL2, monocyte chemotactic activating factor (MCAF) or glioma-derived chemotactic factor-2 (GDCF-2), is the product of the human *JE* gene and a member of the family of C-C (or β) chemokines (1-4). The predicted molecular weight of MCP-1 protein is 11-13 kDa, but it may migrate at 20-30 kDa due to glycosylation. MCP-1 is secreted by a variety of cell types in response to pro-inflammatory stimuli and was originally described for its chemotactic activity on monocytes. This activity has led to studies demonstrating its role in diseases characterized by monocyte infiltrates such as psoriasis (5), rheumatoid arthritis (6) and atherosclerosis (7). MCP-1 may also contribute to tumor progression and angiogenesis (8). Signaling by MCP-1 is mediated by the G protein-coupled receptor CCR2 (9).

Background References

1. Matsushima, K. et al. (1989) *J Exp Med* 169, 1485-90.
2. Furutani, Y. et al. (1989) *Biochem Biophys Res Commun* 159, 249-55.
3. Robinson, E.A. et al. (1989) *Proc Natl Acad Sci USA* 86, 1850-4.
4. Rollins, B.J. et al. (1988) *Proc Natl Acad Sci USA* 85, 3738-42.
5. Gillitzer, R. et al. (1993) *J Invest Dermatol* 101, 127-31.
6. Koch, A.E. et al. (1992) *J Clin Invest* 90, 772-9.
7. Ylä-Herttuala, S. et al. (1991) *Proc Natl Acad Sci USA* 88, 5252-6.
8. Salcedo, R. et al. (2000) *Blood* 96, 34-40.
9. Charo, I.F. et al. (1994) *Proc Natl Acad Sci USA* 91, 2752-6.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting **IP:** Immunoprecipitation

Cross-Reactivity Key

H: Human

Trademarks and Patents

Limited Uses

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.